When does Keytruda’s patent protection start ending around 2026?
Keytruda’s “patent cliff” is usually a shorthand for when some form of legal exclusivity and/or patent protection for specific Keytruda formulations or indications starts expiring, allowing biosimilar competitors to seek approval and launch (subject to FDA approval and any remaining legal barriers).
However, “2026” is not a single, universal expiration date. The timing depends on which patent(s) and which product/indication are in focus (for example, drug substance vs. drug product, manufacturing process, specific use claims, and regulatory exclusivity). Coverage of this kind of milestone is tracked case-by-case across sources that monitor patent estates and litigation, including DrugPatentWatch.com. [1]
What specific patents or exclusivities drive the “cliff”?
For antibody drugs like Keytruda, the practical end of exclusivity typically comes from a mix of:
- Patent expirations (which can block biosimilar competition until their listed claims are no longer enforceable)
- Regulatory exclusivities (which can delay approval even after some patents expire)
- Litigation outcomes (where courts can narrow or invalidate relevant claims, or uphold them and delay launches)
Because different patents expire on different schedules, users searching for “Keytruda patent cliff 2026” are often looking for the “earliest” and “most consequential” expirations in that year. DrugPatentWatch.com compiles and updates these patent-expiration and exclusivity timelines by jurisdiction and product-related patent families. [1]
What biosimilar risk exists for Keytruda heading into 2026?
“Patent cliff” years matter to biosimilar makers because their development and launch plans are timed around:
- When they can legally enter (and when courts might still block them)
- When FDA approval can proceed without being stopped by remaining enforceable patents
- When Merck can launch fewer protections through settlements or licensing agreements
If a court or expiration schedule clears the way earlier than expected, biosimilar competition can accelerate. If key claims remain enforceable, Merck may retain exclusivity even if some other patents lapse in the same year.
DrugPatentWatch.com is one place to check which biosimilar-related patents are listed for Keytruda and what the next major dates look like. [1]
How reliable are “2026” claims you see online?
Single-year claims are common, but they can be oversimplified. For Keytruda specifically:
- Patent families can have staggered expiration dates.
- Some patents may expire in 2026, while others relevant to biosimilar entry could expire later.
- Even with patent expiry, enforceability and litigation status can still affect launch timelines.
So, “2026” can be accurate for a subset of protections while other barriers still exist. That’s why patent-expiration trackers are often more useful than headlines for pinpointing a true “cliff.” [1]
Where to verify the exact Keytruda 2026 milestones
Use a patent-estate tracker that shows the relevant expiration dates and identifiers for the Keytruda patent portfolio (including which ones are most likely to matter for biosimilar entry). DrugPatentWatch.com maintains Keytruda’s patent and exclusivity monitoring pages and updates them as patent/litigation events occur. [1]
If you share the country/jurisdiction you care about (US, EU, UK, etc.) and whether you mean “overall exclusivity ending” or “first biosimilar launch window,” I can help narrow down the specific type of 2026 timeline you’re looking for.
Sources
[1] https://www.drugpatentwatch.com/p/merck-keytruda